Skip to content

Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study

Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02257450
Acronym
MyEndo-PA
Enrollment
2500
Registered
2014-10-06
Start date
2014-10-31
Completion date
2017-06-30
Last updated
2016-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Aldosteronism

Keywords

Primary Aldosteronism, Hyperaldosteronism

Brief summary

This research focuses on the prevalence of Primary Aldosteronism in the Malaysian adult population.

Detailed description

Hypertension (HPT) is a very common disease, expensive to treat with serious morbidity and mortality. In Malaysia, from the NHMS III conducted in 2006, HPT affects more than 36% of adults. Essential HPT (HPT with no identifiable cause) accounts for approximately 85% of cases, whereas 15% have identifiable conditions (secondary cause). The detection of a secondary cause of HPT is important as the condition is reversible when detected early. Primary aldosteronism (PA) has been identified as the commonest cause of secondary HPT. At present, PA has been regarded as the commonest and potentially curable, with a prevalence of 5-13% \[1-7\]. If this condition is detected early, the chances of cure from hypertension have been reported up to 80% of cases. This will translate to a major impact to the Malaysian health-care budget. The costs spent on life-long BP medications and complications related to HPT can be reduced enormously. PA is a type of hormonal disorder that leads to high blood pressure (BP). In PA, the adrenal glands produce too much aldosterone causing sodium retention and potassium excretion. The excess sodium then increased the blood volume and BP. Diagnosis and treatment of this condition are of paramount importance because people with this form of high BP have a higher risk of heart attack, stroke, kidney impairment, metabolic abnormality and reduce quality of life compared to patients with high BP not due to this condition. More importantly, the high BP associated with PA may be curable. This research will be conducted as a multicenter nation-wide study in Malaysia. The research aimed to study the prevalence of this disease in the investigators Malaysian population, determine the underlying mechanisms why this disease is associated with higher complication rate through cardiovascular and inflammatory markers, and identify the genes causing this disease, hence provide a more rapid diagnostic test and possibility of curing the disease with genetic therapy

Interventions

None listed

Sponsors

Malaysian Endocrine and Metabolic Society
CollaboratorOTHER
National University of Malaysia
CollaboratorOTHER
University of Malaya
CollaboratorOTHER
IMU University, Malaysia
CollaboratorOTHER
International Islamic University Malaysia
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years old and above * Malaysian citizen * Consent given

Exclusion criteria

* Those who refused consent

Design outcomes

Primary

MeasureTime frameDescription
Aldosterone-Renin RatioDay 0Aldosterone-renin ratio of respondent at the time of sampling

Secondary

MeasureTime frameDescription
Level of Inflammatory MarkersDay 0Level of inflammatory markers (IL-6, hs-CRP) among respondents at the time of sampling
Level of cardiovascular markersDay 0Level of cardiovascular markers (BNP, PAI-1) among respondents at the time of sampling

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026